Edwards Lifesciences (NYSE:EW) Upgraded at Leerink Partners

Leerink Partners upgraded shares of Edwards Lifesciences (NYSE:EW) from a market perform rating to an outperform rating in a research note published on Friday morning, MarketBeat Ratings reports. The firm currently has $101.00 price objective on the medical research company’s stock.

Several other equities research analysts also recently weighed in on the stock. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research note on Wednesday, April 1st. Citigroup lifted their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Finally, Evercore reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.55.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $82.67 on Friday. The stock has a market cap of $47.60 billion, a price-to-earnings ratio of 47.51, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The stock has a 50 day moving average price of $87.73 and a 200-day moving average price of $83.88. Edwards Lifesciences has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences will post 3 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,671,117.80. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the stock. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter worth approximately $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the 4th quarter worth $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences during the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth $27,000. 79.46% of the stock is currently owned by institutional investors.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.